Chimerix Inc CMRX

NAS: CMRX | ISIN: US16934W1062 17/04/2025

8,540 USD (-0,12%)

(-0,12%) 17/04/2025

Grafiek Chimerix Inc

Grafiek Chimerix Inc

1 dag1d -0,12%
1 week1w 0,00%
1 maand1m 0,47%
3 maanden3m 124,74%
6 maanden6m 762,63%
1 jaar1j 798,95%
5 jaar5j 254,36%

Chimerix Inc in het nieuws

Toon enkel gratis nieuws

5 maart 2025 · Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio · Persbericht

2 maart 2021 · Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference · Persbericht

26 februari 2021 · Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial · Persbericht

25 januari 2021 · Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares · Persbericht

21 januari 2021 · Chimerix Announces Pricing of Public Offering of Common Stock · Persbericht

19 januari 2021 · Chimerix Announces Proposed $75,000,000 Public Offering of Common Stock · Persbericht

8 januari 2021 · Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program · Persbericht

Profiel Chimerix Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.chimerix.com

Hoofdzetel: Durham, North Carolina Verenigde Staten

CEO: Michael Sherman

Werknemers: 103

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe